3974-36-5

Usage

Uses

Used in Pharmaceutical Synthesis:
Hexylmalonic acid is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its ability to react with other compounds allows for the creation of new complex molecules, making it a valuable component in drug development.
Used in Polymer and Adhesive Manufacturing:
Hexylmalonic acid is utilized in the production of polymers and adhesives. Its chemical properties enable it to form strong bonds and contribute to the overall performance and stability of these materials.
Used in Chemical Industry:
Hexylmalonic acid has a wide range of applications in the chemical industry due to its reactivity with other compounds. It can be used to form new complex molecules, making it a versatile building block for various chemical processes and products.

InChI:InChI=1/C9H16O4/c1-2-3-4-5-6-7(8(10)11)9(12)13/h7H,2-6H2,1H3,(H,10,11)(H,12,13)

Upstream product

• 5398-10-7 diethyl 2-hexylmalonate 
• 638-45-9 1-Iodohexane 
• 122459-92-1 Hexylmalonsaeure-dimethylester 
• 111-64-8 n-octanoic acid chloride 
• 92017-12-4 Antimycinolactol A₁ 
• 108127-84-0 hexylmalonyl dichloride 

Downstream Products

• 644-90-6 2-aminooctanoic acid 
• 56705-47-6 1-phenyldecan-3-one 
• 2623-82-7 2-bromooctanoic acid 
• 100905-25-7 1-phenyldec-1-yn-3-one 

Relevant academic research and scientific papers

Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth

Despite the increasing incidence of hepatocellular carcinoma (HCC) worldwide, current pharmacological treatments are still unsatisfactory. We have previously shown that lysophosphatidic acid receptor 6 (LPAR6) supports HCC growth and that 9-xanthenylacetic acid (XAA) acts as an LPAR6 antagonist inhibiting HCC growth without toxicity. Here, we synthesized four novel XAA derivatives, (±)-2-(9H-xanthen-9-yl)propanoic acid (compound 4 – MC9), (±)-2-(9H-xanthen-9-yl)butanoic acid (compound 5 – MC6), (±)-2-(9H-xanthen-9-yl)hexanoic acid (compound 7 – MC11), and (±)-2-(9H-xanthen-9-yl)octanoic acid (compound 8 – MC12, sodium salt) by introducing alkyl groups of increasing length at the acetic α-carbon atom. Two of these compounds were characterized by X-ray powder diffraction and quantum mechanical calculations, while molecular docking simulations suggested their enantioselectivity for LPAR6. Biological data showed anti-HCC activity for all XAA derivatives, with the maximum effect observed for MC11. Our findings support the view that increasing the length of the alkyl group improves the inhibitory action of XAA and that enantioselectivity can be exploited for designing novel and more effective XAA-based LPAR6 antagonists.

Ni-Catalyzed Enantioselective Reductive Diarylation of Activated Alkenes by Domino Cyclization/Cross-Coupling

A Ni-catalyzed enantioselective reductive diarylation of activated alkenes by domino cyclizative/cross-coupling of two aryl bromides is developed. This reaction proceeds under very mild conditions and shows broad substrate scope, without requiring the use of preformed organometallic reagents. Moreover, this approach provides direct access to various bis-heterocycles bearing all-carbon quaternary centers in synthetically useful yields (up to 81%) with excellent enantioselectivity (>30 examples, 90-99% ee).